SOPH Nasdaq Services-Computer Processing & Data Preparation Financials FY2019βFY2025
SOPHiA GENETICS SA had $77.3M of revenue in fiscal 2025, up 18.6% on the year before. Over five years, revenue changed +22.2% a year on average.
Last close Β· Oct 23, 2026
$7.35
4.3%Hi! I read SOPHiA GENETICS SAβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+18.6%
Yes. Sales grew 18.6% last year.
Does it make a profit?
β102.2%
No. It lost money last year.
Does profit turn into cash?
β47.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days SOPHiA GENETICS SA did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Mar 3, 2026 | Period ended Dec 31, 2025 | Before the market opens | 20-F β |
| Mar 4, 2025 | Period ended Dec 31, 2024 | Before the market opens | 20-F β |
| Mar 5, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| Mar 7, 2023 | Period ended Dec 31, 2022 | Before the market opens | 20-F β |
| Mar 15, 2022 | Period ended Dec 31, 2021 | Before the market opens | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· SOPHiA GENETICS SA had $77.3M of revenue in fiscal 2025, up 18.6% on the year before. Over five years, revenue changed +22.2% a year on average. Its operating margin was β91.8%, up 10.4Β pts: of every 100 in sales, about β92 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· SOPHiA GENETICS SA lost $79.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$36.5M in fiscal 2025, β47.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.1M and sold $4.4M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
1 insider
Sold, 12 months
$4.4M
10 insiders
Of sales under plans
100%
$4.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | George CardozaChief Financial Officer | Sold plan | 774 | $8.33 | $0.0M | Form 4 |
| Sep 21, 2026 | Ross MukenChief Executive Officer, Director | Sold plan | 422 | $8.33 | $0.0M | Form 4 |
| Sep 14, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $7.88 | $0.0M | Form 4 |
| Sep 14, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,000 | $7.88 | $0.0M | Form 4 |
| Sep 11, 2026 | Daan Van WellChief Legal Officer | Sold plan | 6,168 | $7.63 | $0.0M | Form 4 |
| Sep 10, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 8,500 | $7.66 | $0.1M | Form 4 |
| Sep 8, 2026 | Kathy L HibbsDirector | Sold plan | 6,250 | $8.13 | $0.1M | Form 4 |
| Aug 27, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 10,000 | $8.91 | $0.1M | Form 4 |
| Aug 25, 2026 | Kathy L HibbsDirector | Sold plan | 6,250 | $8.68 | $0.1M | Form 4 |
| Aug 25, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $8.68 | $0.0M | Form 4 |
| Aug 24, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 5,000 | $8.80 | $0.0M | Form 4 |
| Aug 21, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 5,408 | $8.40 | $0.0M | Form 4 |
| Aug 20, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,592 | $8.41 | $0.0M | Form 4 |
| Aug 19, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 5,000 | $8.20 | $0.0M | Form 4 |
| Aug 19, 2026 | Manuela ValenteChief People Officer | Sold plan | 10,000 | $7.94 | $0.1M | Form 4 |
| Aug 19, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 10,000 | $7.94 | $0.1M | Form 4 |
| Aug 13, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,000 | $7.52 | $0.0M | Form 4 |
| Aug 12, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $7.52 | $0.0M | Form 4 |
| Aug 10, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 8,500 | $7.61 | $0.1M | Form 4 |
| Aug 7, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 5,000 | $7.60 | $0.0M | Form 4 |
| Aug 7, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 20,000 | $7.23 | $0.1M | Form 4 |
| Aug 7, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 17,000 | $7.29 | $0.1M | Form 4 |
| Aug 5, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 3,000 | $7.00 | $0.0M | Form 4 |
| Aug 4, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 5,000 | $6.95 | $0.0M | Form 4 |
| Aug 4, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 20,000 | $6.92 | $0.1M | Form 4 |
| Aug 4, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 10,000 | $6.92 | $0.1M | Form 4 |
| Jul 27, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $5.66 | $0.0M | Form 4 |
| Jul 21, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 20,000 | $6.63 | $0.1M | Form 4 |
| Jul 20, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 24,381 | $6.29 | $0.2M | Form 4 |
| Jul 13, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $5.70 | $0.0M | Form 4 |
| Jul 13, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,000 | $5.70 | $0.0M | Form 4 |
| Jul 10, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 8,500 | $5.62 | $0.0M | Form 4 |
| Jul 7, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 17,685 | $5.28 | $0.1M | Form 4 |
| Jul 6, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 5,285 | $5.10 | $0.0M | Form 4 |
| Jul 6, 2026 | George CardozaChief Financial Officer | Sold plan | 1,592 | $5.29 | $0.0M | Form 4 |
| Jul 6, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 22,486 | $5.26 | $0.1M | Form 4 |
| Jul 6, 2026 | Kevin PuylaertChief Sales Officer | Sold | 216 | $5.04 | $0.0M | Form 4 |
| Jul 6, 2026 | Manuela ValenteChief People Officer | Sold plan | 4,241 | $5.05 | $0.0M | Form 4 |
| Jul 6, 2026 | Philippe MenuChief Medical Officer | Sold plan | 7,393 | $5.16 | $0.0M | Form 4 |
| Jul 6, 2026 | Ross MukenChief Executive Officer, Director | Sold plan | 9,838 | $5.22 | $0.1M | Form 4 |
| Jul 6, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 7,393 | $5.17 | $0.0M | Form 4 |
| Jun 30, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 65,269 | $6.10 | $0.4M | Form 4 |
| Jun 29, 2026 | Jurgi CamblongExecutive Chairman, Director | Sold plan | 18,410 | $5.87 | $0.1M | Form 4 |
| Jun 26, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 50,069 | $5.80 | $0.3M | Form 4 |
| Jun 25, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 6,944 | $5.51 | $0.0M | Form 4 |
| Jun 25, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 1,373 | $5.70 | $0.0M | Form 4 |
| Jun 25, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $5.50 | $0.0M | Form 4 |
| Jun 22, 2026 | George CardozaChief Financial Officer | Sold plan | 774 | $5.38 | $0.0M | Form 4 |
| Jun 22, 2026 | Ross MukenPresident | Sold plan | 422 | $5.38 | $0.0M | Form 4 |
| Jun 15, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,000 | $5.01 | $0.0M | Form 4 |
| Jun 12, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $4.95 | $0.0M | Form 4 |
| Jun 10, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 8,500 | $5.24 | $0.0M | Form 4 |
| Jun 5, 2026 | George CardozaChief Financial Officer | Bought | 20,000 | $4.95 | $0.1M | Form 4 |
| May 26, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $4.95 | $0.0M | Form 4 |
| May 19, 2026 | Daan Van WellChief Legal Officer | Sold plan | 684 | $4.60 | $0.0M | Form 4 |
| May 19, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 4,486 | $4.60 | $0.0M | Form 4 |
| May 19, 2026 | Kevin PuylaertChief Sales Officer | Sold | 33 | $4.54 | $0.0M | Form 4 |
| May 19, 2026 | Manuela ValenteChief People Officer | Sold plan | 380 | $4.60 | $0.0M | Form 4 |
| May 19, 2026 | Philippe MenuChief Medical Officer | Sold plan | 608 | $4.61 | $0.0M | Form 4 |
| May 19, 2026 | Ross MukenPresident | Sold plan | 761 | $4.60 | $0.0M | Form 4 |
| May 19, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 608 | $4.60 | $0.0M | Form 4 |
| May 13, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,000 | $4.54 | $0.0M | Form 4 |
| May 12, 2026 | Kathy L HibbsDirector | Sold plan | 7,508 | $4.67 | $0.0M | Form 4 |
| May 12, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $4.67 | $0.0M | Form 4 |
| May 11, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 8,500 | $5.09 | $0.0M | Form 4 |
| Apr 27, 2026 | Philippe MenuChief Medical Officer | Sold plan | 5,000 | $4.82 | $0.0M | Form 4 |
| Apr 20, 2026 | Daan Van WellChief Legal Officer | Sold plan | 684 | $5.20 | $0.0M | Form 4 |
| Apr 20, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 4,486 | $5.21 | $0.0M | Form 4 |
| Apr 20, 2026 | Kevin PuylaertChief Sales Officer | Sold | 33 | $5.08 | $0.0M | Form 4 |
| Apr 20, 2026 | Manuela ValenteChief People Officer | Sold plan | 380 | $5.20 | $0.0M | Form 4 |
| Apr 20, 2026 | Philippe MenuChief Medical Officer | Sold plan | 608 | $5.20 | $0.0M | Form 4 |
| Apr 20, 2026 | Ross MukenPresident | Sold plan | 760 | $5.20 | $0.0M | Form 4 |
| Apr 20, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 608 | $5.21 | $0.0M | Form 4 |
| Apr 15, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 17,473 | $5.00 | $0.1M | Form 4 |
| Apr 14, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 43,129 | $4.96 | $0.2M | Form 4 |
| Apr 14, 2026 | Philippe MenuChief Medical Officer | Sold plan | 1,600 | $4.96 | $0.0M | Form 4 |
| Apr 14, 2026 | Ross MukenPresident | Sold plan | 2,800 | $4.96 | $0.0M | Form 4 |
| Apr 14, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 600 | $4.97 | $0.0M | Form 4 |
| Apr 13, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 4,399 | $4.76 | $0.0M | Form 4 |
| Apr 13, 2026 | Philippe MenuChief Medical Officer | Sold plan | 4,400 | $4.76 | $0.0M | Form 4 |
| Apr 13, 2026 | Ross MukenPresident | Sold plan | 4,442 | $4.77 | $0.0M | Form 4 |
| Apr 13, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 4,414 | $4.76 | $0.0M | Form 4 |
| Apr 10, 2026 | Daan Van WellChief Legal Officer | Sold plan | 2,400 | $4.67 | $0.0M | Form 4 |
| Apr 10, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 12,232 | $4.72 | $0.1M | Form 4 |
| Apr 10, 2026 | Philippe MenuChief Medical Officer | Sold plan | 3,725 | $4.68 | $0.0M | Form 4 |
| Apr 10, 2026 | Ross MukenPresident | Sold plan | 3,687 | $4.69 | $0.0M | Form 4 |
| Apr 10, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 3,706 | $4.68 | $0.0M | Form 4 |
| Apr 9, 2026 | Daan Van WellChief Legal Officer | Sold plan | 1,988 | $4.74 | $0.0M | Form 4 |
| Apr 9, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 1,950 | $4.74 | $0.0M | Form 4 |
| Apr 9, 2026 | Philippe MenuChief Medical Officer | Sold plan | 1,931 | $4.74 | $0.0M | Form 4 |
| Apr 9, 2026 | Ross MukenPresident | Sold plan | 1,950 | $4.74 | $0.0M | Form 4 |
| Apr 9, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 1,936 | $4.74 | $0.0M | Form 4 |
| Apr 8, 2026 | Daan Van WellChief Legal Officer | Sold plan | 2,861 | $4.85 | $0.0M | Form 4 |
| Apr 8, 2026 | George CardozaChief Financial Officer | Sold plan | 1,403 | $4.85 | $0.0M | Form 4 |
| Apr 8, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 2,800 | $4.84 | $0.0M | Form 4 |
| Apr 8, 2026 | Manuela ValenteChief People Officer | Sold plan | 3,824 | $4.85 | $0.0M | Form 4 |
| Apr 8, 2026 | Philippe MenuChief Medical Officer | Sold plan | 2,800 | $4.84 | $0.0M | Form 4 |
| Apr 8, 2026 | Ross MukenPresident | Sold plan | 2,786 | $4.84 | $0.0M | Form 4 |
| Apr 8, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 2,800 | $4.84 | $0.0M | Form 4 |
| Apr 7, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 1,030 | $4.87 | $0.0M | Form 4 |
| Apr 7, 2026 | Daan Van WellChief Legal Officer | Sold plan | 2,400 | $4.87 | $0.0M | Form 4 |
| Apr 7, 2026 | George CardozaChief Financial Officer | Sold plan | 2,413 | $4.88 | $0.0M | Form 4 |
| Apr 7, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 2,500 | $4.86 | $0.0M | Form 4 |
| Apr 7, 2026 | Manuela ValenteChief People Officer | Sold plan | 2,376 | $4.87 | $0.0M | Form 4 |
| Apr 7, 2026 | Philippe MenuChief Medical Officer | Sold plan | 2,400 | $4.87 | $0.0M | Form 4 |
| Apr 7, 2026 | Ross MukenPresident | Sold plan | 2,424 | $4.87 | $0.0M | Form 4 |
| Apr 7, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 2,400 | $4.87 | $0.0M | Form 4 |
| Apr 6, 2026 | Abhimanyu VermaChief Technology Officer | Sold plan | 2,519 | $4.86 | $0.0M | Form 4 |
| Apr 6, 2026 | Daan Van WellChief Legal Officer | Sold plan | 2,705 | $4.86 | $0.0M | Form 4 |
| Apr 6, 2026 | George CardozaChief Financial Officer | Sold plan | 2,520 | $4.85 | $0.0M | Form 4 |
| Apr 6, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 2,600 | $4.85 | $0.0M | Form 4 |
| Apr 6, 2026 | Kevin PuylaertChief Sales Officer | Sold | 624 | $4.86 | $0.0M | Form 4 |
| Apr 6, 2026 | Manuela ValenteChief People Officer | Sold plan | 2,597 | $4.85 | $0.0M | Form 4 |
| Apr 6, 2026 | Philippe MenuChief Medical Officer | Sold plan | 2,700 | $4.85 | $0.0M | Form 4 |
| Apr 6, 2026 | Ross MukenPresident | Sold plan | 2,600 | $4.85 | $0.0M | Form 4 |
| Apr 6, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 2,700 | $4.85 | $0.0M | Form 4 |
| Mar 31, 2026 | Kevin PuylaertChief Sales Officer | Sold | 3 | $4.71 | $0.0M | Form 4 |
| Mar 19, 2026 | Daan Van WellChief Legal Officer | Sold plan | 684 | $4.79 | $0.0M | Form 4 |
| Mar 19, 2026 | George CardozaChief Financial Officer | Sold plan | 774 | $4.79 | $0.0M | Form 4 |
| Mar 19, 2026 | Jurgi CamblongChief Executive Officer, Director | Sold plan | 4,486 | $4.77 | $0.0M | Form 4 |
| Mar 19, 2026 | Kevin PuylaertChief Sales Officer | Sold | 33 | $4.76 | $0.0M | Form 4 |
| Mar 19, 2026 | Manuela ValenteChief People Officer | Sold plan | 380 | $4.79 | $0.0M | Form 4 |
| Mar 19, 2026 | Philippe MenuChief Medical Officer | Sold plan | 608 | $4.79 | $0.0M | Form 4 |
| Mar 19, 2026 | Ross MukenPresident | Sold plan | 1,183 | $4.79 | $0.0M | Form 4 |
| Mar 19, 2026 | Zhenyu XuChief Scientific Officer | Sold plan | 608 | $4.78 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· SOPHiA GENETICS SA has $22.6M more cash than debt.
Cash, debt and the ratios that show how comfortably SOPHiA GENETICS SA can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $193M | $161M | $123M | $80.2M | $70.3M |
| Debt incl. finance leases | $0.0M | β | $0.0M | $13.2M | $47.7M |
| Debt / equity | 0.0x | β | 0.0x | 0.1x | 1.0x |
| Interest coverage | β108.6x | β137.4x | β127.3x | β34.8x | β15.6x |
| Current ratio | 9.9x | 7.3x | 4.2x | 3.7x | 2.0x |
| Quick ratio | 9.7x | 7.1x | 4.0x | 3.5x | 1.8x |
| Total assets | $320M | $244M | $206M | $155M | $163M |
| Total liabilities | $44.8M | $43.7M | $54.7M | $58.8M | $116M |
| Shareholders' equity | $275M | $200M | $151M | $96.5M | $47.1M |
| Net debt (β = net cash) | β$193M | β | β$123M | β$67.0M | β$22.6M |
KIRA Β· Its return on capital was β227.8%: every 100 invested in the business earned about β228 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· SOPHiA GENETICS SA passes 2 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 5 / 9 | 3 / 8 | 3 / 8 | 2 / 9 | 2 / 9 |
| Accruals ratio | β | β5.8% | β7.0% | β6.2% | β11.4% | β9.9% | β27.1% |
| Altman Z'' | β | 2.42 | 8.02 | 2.95 | β1.93 | β7.33 | β10.93 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $25.4M | $28.4M | $40.5M | $47.6M | $62.4M | $65.2M | $77.3M |
| Net interest income | $0.1M | $0.1M | β$0.6M | $0.7M | $4.0M | β | β |
| Gross profit | $17.8M | $17.7M | $25.2M | $31.3M | $42.9M | $43.9M | $52.1M |
| Research and development | $15.0M | $18.6M | $26.6M | $35.4M | $37.0M | $34.4M | $34.2M |
| Operating income | β | β$37.4M | β$71.5M | β$87.8M | β$74.8M | β$66.6M | β$70.9M |
| Interest expense | $1.0M | $0.8M | $0.7M | $0.6M | $0.6M | $1.9M | $4.6M |
| Pretax income | β$33.6M | β$41.2M | β$73.5M | β$87.6M | β$78.5M | β$61.3M | β$77.5M |
| Income tax | $0.2M | β$1.9M | $0.2M | β$0.1M | $0.5M | $1.2M | $1.5M |
| Net income | β$33.8M | β$39.3M | β$73.7M | β$87.4M | β$79.0M | β$62.5M | β$79.0M |
| Net income to common | β$33.8M | β$39.3M | β$73.7M | β$87.4M | β$79.0M | β$62.5M | β$79.0M |
| Diluted EPS | β | β$0.93 | β$1.33 | β$1.36 | β$1.22 | β$0.95 | β$1.17 |
| Diluted shares | β | 0.04B | 0.06B | 0.06B | 0.06B | 0.07B | 0.07B |
| Cash flow | |||||||
| Cash from operations | β$31.7M | β$31.7M | β$57.9M | β$70.1M | β$53.2M | β$44.5M | β$35.9M |
| Capital expenditure | $1.4M | $0.5M | $2.7M | $4.1M | $1.5M | $0.2M | $0.6M |
| Free cash flow | β$33.0M | β$32.2M | β$60.6M | β$74.2M | β$54.7M | β$44.8M | β$36.5M |
| Stock-based compensation | $0.7M | $1.4M | $8.5M | $13.6M | $15.2M | $16.5M | $16.2M |
| Balance sheet | |||||||
| Cash and short-term investments | $18.1M | $74.6M | $193M | $161M | $123M | $80.2M | $70.3M |
| Total debt | $3.8M | $3.3M | $0.0M | β | $0.0M | $13.2M | $47.7M |
| Current assets | β | $110M | $283M | $196M | $148M | $99.4M | $99.1M |
| Current liabilities | β | $21.6M | $28.6M | $26.8M | $35.6M | $26.8M | $50.5M |
| Inventory | β | $3.4M | $5.7M | $5.2M | $6.5M | $5.9M | $6.4M |
| Property and equipment, net | β | $1.8M | $4.7M | $7.1M | $7.5M | $5.2M | $5.7M |
| Intangible assets | β | $13.3M | $15.7M | $20.0M | $27.2M | $29.0M | $35.9M |
| Total assets | β | $132M | $320M | $244M | $206M | $155M | $163M |
| Total liabilities | β | $31.6M | $44.8M | $43.7M | $54.7M | $58.8M | $116M |
| Shareholders' equity | $22.3M | $101M | $275M | $200M | $151M | $96.5M | $47.1M |
| Margins | |||||||
| Gross margin | 70.3% | 62.3% | 62.4% | 65.7% | 68.8% | 67.4% | 67.4% |
| Operating margin | β | β131.6% | β176.7% | β184.7% | β120.0% | β102.1% | β91.8% |
| Net margin | β133.2% | β138.5% | β182.1% | β183.9% | β126.6% | β95.9% | β102.2% |
| FCF margin | β130.3% | β113.3% | β149.9% | β156.0% | β87.7% | β68.7% | β47.2% |
| Net interest share of revenue | 0.3% | 0.3% | β1.6% | 1.4% | 6.3% | β | β |
| Returns | |||||||
| Return on capital | β | β101.1% | β68.5% | β | β209.7% | β178.3% | β227.8% |
| Return on capital employed | β | β33.8% | β24.5% | β40.5% | β43.9% | β51.8% | β63.0% |
| Return on equity | β151.8% | β64.1% | β39.2% | β36.8% | β44.9% | β50.4% | β110.0% |
| Return on assets | β | β29.8% | β32.6% | β31.0% | β35.1% | β34.6% | β49.6% |
| Return on tangible equity | β151.8% | β45.1% | β28.4% | β48.5% | β63.6% | β92.6% | β702.0% |
| Growth | |||||||
| Revenue growth | β | 12.0% | 42.4% | 17.6% | 31.1% | 4.5% | 18.6% |
| Share count change | β | β | 30.6% | 15.9% | 1.0% | 2.0% | 2.2% |
| Financial health | |||||||
| Debt / equity | 0.2x | 0.0x | 0.0x | β | 0.0x | 0.1x | 1.0x |
| Interest coverage | β | β44.5x | β108.6x | β137.4x | β127.3x | β34.8x | β15.6x |
| Current ratio | β | 5.1x | 9.9x | 7.3x | 4.2x | 3.7x | 2.0x |
| Quick ratio | β | 4.9x | 9.7x | 7.1x | 4.0x | 3.5x | 1.8x |
| Capital allocation | |||||||
| Capex / revenue | 5.3% | 1.6% | 6.6% | 8.6% | 2.4% | 0.4% | 0.7% |
| Stock comp / revenue | 2.8% | 4.8% | 21.0% | 28.6% | 24.4% | 25.3% | 21.0% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 5.0 | 3.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | β | 2.4 | 8.0 | 3.0 | β1.9 | β7.3 | β10.9 |
| Accruals ratio | β | β5.8% | β7.0% | β6.2% | β11.4% | β9.9% | β27.1% |
Source: SEC EDGAR XBRL filings (CIK 0001840706). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
